ERBB2 and inflammatory breast carcinoma: For the 117 cases of IBC, 87 out of 117 (74.36%) were identified ER-positive and 30/117 (25.64%) were negative, 73 out of 117 (62.39%) were identified PR-positive and 44/117 (37.61%) were negative, 46 out of 117 (39.32%) were identified HER-2-positive and 71/117 (60.68%) were negative, 104 out of 117 (88.89%) were identified high expression of Ki-67 and 13/117 (11.11%) were low expression of Ki-67.